

Press Release

N°: 2006/01

from [Neurotune AG](#)

Neurotune appoints new CEO

Dr. Andreas J. Schulze is new CEO of Neurotune AG.

Schlieren, 06. Februar 2006. Neurotune today announced that its board of directors has appointed Dr. Andreas J. Schulze as the new Chief Executive Officer. The appointee takes over from Nicolas Berg, who will leave to pursue opportunities outside the company.

Andreas Schulze is a biochemist who graduated from Max-Planck-Institute of Biochemistry. He expanded his knowledge into the field of economics with an in-service training. His professional experience in research management in the pharmaceutical and diagnostics industry he gained when working for former Marion Merrell-Dow, Strasbourg, France and Pentapharm, Basel, Switzerland.

In the past years Andreas Schulze has managed the biotech portfolio of the Jena- based Venture Capital firm DEWB AG.

“We are pleased to have Andreas Schulze on board as the new CEO in this challenging phase. His scientific background in combination with his business experience will be of great value in building the company...” Dr. Bruno Oesch, President of the Board of Directors of Neurotune, says.

Contact:

Mrs. Theres Oesch
Assistant to the CEO

neurotune ag

Waghstrasse 27A

8952 Schlieren (Zurich)

Switzerland

Phone +41 44 200 21 95

Fax +41 44 200 20 10

toe@neurotune.com

About Neurotune AG

Neurotune was incorporated in January 2005 as a spin-off from Prionics AG and has found its seat in Schlieren (Zurich), Switzerland.

Neurotune develops small-molecular drugs to treat disorders of the human nervous system (peripheral and central). First priority is given to drugs to treat age-related muscle atrophy - Sarcopenia, second priority to drugs for rehabilitation therapies after stroke or traumatic brain injury, and third priority is given to drugs for treatment of other CNS disturbances.

About Sarcopenia

With age, progressive muscle degeneration leads to reduced strength ensuing problems such as frequent falls. The age-related muscle atrophy – Sarcopenia - is defined as the loss of muscle mass and strength with aging, and plays a major role in the pathogenesis of frailty and functional impairment that occurs with the elderly. It correlates with the loss of muscular strength, decreased metabolic rate, gradual reduction of bone density, and decreased aerobic capacity.

Sarcopenia - is a growing market with no available causal treatment.

* * * * *